Vaxcyte, Inc.
Vaxcyte, Inc. is a U.S.-based biotechnology company developing protein-based vaccines, with a primary focus on pneumococcal conjugate vaccine candidates. Its pipeline also includes other preclinical vaccine programs built on a cell-free protein synthesis platform, and its work is centered on research, development, and outsourced manufacturing rather than internal commercial production.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueConjugate vaccine candidates designed to prevent pneumococcal disease across adult and pediatric populations.
Preclinical vaccine programs targeting infectious diseases such as Group A Strep and Shigella.
Proprietary platform used to produce vaccine components and enable scalable conjugate vaccine manufacturing.
Customers
Vaxcyte does not sell commercial products today; its end customers are future vaccine purchasers such as healthcare systems, public health programs, and private providers if its candidates are approved. In the development phase, the company’s direct counterparties are research collaborators, contract manufacturers, clinical sites, and government-funded research partners that support advancement of the pipeline.
Would buy PCV products for adult immunization against pneumococcal disease if approved.
Would buy PCV products for infant and child immunization programs if approved.
CROs, clinical sites, and investigators that execute trials and generate data.
CMOs such as Lonza and Thermo Fisher that supply drug substance, extract, and fill-finish.
Universities and NIH-supported partners that help advance early-stage programs.
Strategy
Vaxcyte’s strategy is to advance broad-spectrum pneumococcal vaccine candidates toward regulatory approval while building a scalable manufacturing path that can support launch. It is also extending its platform into additional infectious-disease programs, but near-term resources are concentrated on the PCV franchise and on securing outsourced production capacity and intellectual property control.
PCV candidates are the core value driver and the most advanced programs.
Commercial viability depends on reliable, high-quality vaccine supply at scale.
Control over cell-free extract and conjugate methods supports differentiation and supply security.
Early-stage programs can expand the pipeline without distracting from the lead franchise.
Geography
Vaxcyte is headquartered in the United States and its development and manufacturing network is centered in the U.S. and Europe through third-party partners. The company’s commercial planning is oriented toward the U.S. first, while its vaccine programs are intended for global markets and rely on international manufacturing and supply relationships.
Risks
Vaxcyte faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and the need for substantial external funding before any product revenue exists. Its business also depends heavily on third-party manufacturers and licensed technology, so supply interruptions, quality issues, or IP disputes could materially affect development and launch plans.
- Clinical development failure or delayImpact: HighLikelihood: Medium
Lead candidates must show safety, tolerability, and efficacy before approval.
Exposure - Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company does not own commercial manufacturing facilities and relies on CMOs.
Exposure - Funding and dilution riskImpact: HighLikelihood: Medium
Development and commercialization require substantial additional capital.
Exposure: Equity and other external financing
- Regulatory and approval riskImpact: HighLikelihood: Medium
Vaccine candidates may face delays or requests for additional data from agencies.
Exposure: U.S. and global vaccine approvals
- Public perception of vaccinesImpact: MediumLikelihood: Medium
Negative sentiment can affect trial enrollment, adoption, and approval dynamics.
Exposure: Vaccine category broadly
Accounting
Judgemental itemsClinical and manufacturing services are often billed after work is performed, requiring estimates.
Impact: Can shift expenses between periods and affect comparability
A meaningful non-cash expense for a development-stage biotech with equity-based pay.
Impact: Affects operating loss and per-share metrics
Lab and office leases create right-of-use assets and lease liabilities.
Impact: Affects balance sheet leverage and operating expense presentation
Program pauses or setbacks can trigger write-down considerations.
Impact: Could create non-cash charges if projects lose value
Similar listed companies
Publicly listed companies with a comparable business focus.
MaxCyte, Inc
MXCT · Services-Commercial Physical & Biological Research
MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family.
Vaxart, Inc.
VXRT · Biological Products, (No Diagnostic Substances)
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Novavax, Inc
NVAX · Biological Products, (No Diagnostic Substances)
Novavax is a U.S.-based biotechnology company focused on developing and commercializing protein-based vaccines and vaccine-related technologies.
PharmaCyte Biotech, Inc.
PMCB · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026